These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8248532)

  • 1. What have we learned from the THA trials to facilitate testing of new AChE inhibitors.
    Gauthier S; Gauthier L
    Prog Brain Res; 1993; 98():427-9. PubMed ID: 8248532
    [No Abstract]   [Full Text] [Related]  

  • 2. Side effects of long acting cholinesterase inhibitors.
    Beermann B
    Acta Neurol Scand Suppl; 1993; 149():53-4. PubMed ID: 8128840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing the tolerability of tacrine with propantheline.
    Faber RA; Negro PJ
    Am J Psychiatry; 1999 Jan; 156(1):156. PubMed ID: 9892315
    [No Abstract]   [Full Text] [Related]  

  • 4. No association between tacrine transaminitis and the glutathione transferase theta genotype in patients with Alzheimer's disease.
    De Sousa M; Pirmohamed M; Kitteringham NR; Woolf T; Park BK
    Pharmacogenetics; 1998 Aug; 8(4):353-5. PubMed ID: 9731722
    [No Abstract]   [Full Text] [Related]  

  • 5. [Tacrine against Alzheimer disease? Still uncertain for which patients may the treatment be beneficial].
    Wallin A
    Lakartidningen; 1996 Jan; 93(1-2):22-4. PubMed ID: 8544526
    [No Abstract]   [Full Text] [Related]  

  • 6. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease: the role of tacrine therapy.
    Jogerst G
    Iowa Med; 1995 Oct; 85(10):409-11. PubMed ID: 7591656
    [No Abstract]   [Full Text] [Related]  

  • 8. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.
    Gauthier S; Bouchard R; Lamontagne A; Bailey P; Bergman H; Ratner J; Tesfaye Y; Saint-Martin M; Bacher Y; Carrier L
    N Engl J Med; 1990 May; 322(18):1272-6. PubMed ID: 2183056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic trials using tacrine and other cholinesterase inhibitors.
    Gamzu ER; Thal LJ; Davis KL
    Adv Neurol; 1990; 51():241-5. PubMed ID: 2403716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease.
    Hier DB
    Surg Neurol; 1997 Jan; 47(1):84-5. PubMed ID: 8986173
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacoepidemiology of tacrine in Alzheimer's disease.
    Begaud B; Haramburu F; Miremont G
    Methods Find Exp Clin Pharmacol; 1996; 18 Suppl B():77-8. PubMed ID: 8899701
    [No Abstract]   [Full Text] [Related]  

  • 12. Cholinergic delirium and neurotoxicity associated with tacrine for Alzheimer's dementia.
    Trzepacz PT; Ho V; Mallavarapu H
    Psychosomatics; 1996; 37(3):299-301. PubMed ID: 8849507
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical study of patients with Alzheimer's disease under treatment with tacrine].
    García-López MT; Guardado-Santervás P
    Rev Neurol; 2001 Feb 16-28; 32(4):394-7. PubMed ID: 11398762
    [No Abstract]   [Full Text] [Related]  

  • 14. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group.
    Foster NL; Petersen RC; Gracon SI; Lewis K
    Dementia; 1996; 7(5):260-6. PubMed ID: 8872417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance to tacrine, arterial hypotension and leuko-araiosis in Alzheimer's disease.
    Lebert F; Mouly C; Pasquier F
    Age Ageing; 1998 Sep; 27(5):654. PubMed ID: 12675108
    [No Abstract]   [Full Text] [Related]  

  • 16. Donepezil: new preparation. Moderate efficacy in Alzheimer's disease.
    Prescrire Int; 1998 Oct; 7(37):146-7. PubMed ID: 10915420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience.
    Gracon SI; Knapp MJ; Berghoff WG; Pierce M; DeJong R; Lobbestael SJ; Symons J; Dombey SL; Luscombe FA; Kraemer D
    Alzheimer Dis Assoc Disord; 1998 Jun; 12(2):93-101. PubMed ID: 9651138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticholinesterases in Alzheimer's disease: a modest effect on moderately severe disease.
    Prescrire Int; 2003 Dec; 12(68):230-1. PubMed ID: 14986699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharma-clinics. Drug of the month. Tacrine (Cognex)].
    Scheen AJ
    Rev Med Liege; 1996 May; 51(5):379-81. PubMed ID: 8992561
    [No Abstract]   [Full Text] [Related]  

  • 20. A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease.
    Samuels SC; Davis KL
    Drug Saf; 1997 Jan; 16(1):66-77. PubMed ID: 9010644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.